Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Finance

Antibiotic developer Achaogen files for bankruptcy

by Michael McCoy
April 20, 2019 | A version of this story appeared in Volume 97, Issue 16

 

The structure of Zemdri.

Despite winning US Food and Drug Administration approval for a new antibiotic last year, Achaogen has filed for bankruptcy. The South San Francisco–based biotech firm launched the antibiotic, Zemdri (plazomicin), in July for adults with complicated urinary tract infections. However, by the end of the year the drug had brought in only $800,000 in sales. Achaogen hopes to sell off its assets, including Zemdri, by June 13.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.